Evidence map›Paper›PMID 36298846›Full record

ArticleViruses2022

Natural History of Marburg Virus Infection to Support Medical Countermeasure Development.

Jason E Comer, Trevor Brasel, Shane Massey, David W Beasley, Chris M Cirimotich, Daniel C Sanford, Ying-Liang Chou, Nancy A Niemuth, Joseph Novak, Carol L Sabourin and 4 more

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Marburg Virus Medical Countermeasures.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Jason E ComerDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Trevor BraselDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Shane MasseyInstitutional Office of Regulated Nonclinical Studies, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
David W BeasleyDepartment of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Galveston, TX 77555, USA.
Chris M CirimotichBattelle Biomedical Research Center, West Jefferson, OH 43162, USA.ORCID 0000-0002-7636-0542
Daniel C SanfordBattelle Biomedical Research Center, West Jefferson, OH 43162, USA.
Ying-Liang ChouBattelle Biomedical Research Center, West Jefferson, OH 43162, USA.
Nancy A NiemuthBattelle Biomedical Research Center, West Jefferson, OH 43162, USA.ORCID 0000-0001-5166-7743
Joseph NovakAmplifyBio, West Jefferson, OH 43162, USA.
Carol L SabourinTunnell Government Services, Inc., Supporting Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA.
Michael MerchlinskyCBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA.
James P LongTunnell Government Services, Inc., Supporting Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA.
Eric J StavaleCBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA.
Daniel N WolfeCBRN Vaccines, Biomedical Advanced Research & Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), U.S. Department of Health and Human Services (DHHS), Washington, DC 20201, USA.ORCID 0000-0002-8392-9506
Biomedical Advanced Research and Development Authority · USBattelle · USThe University of Texas Medical Branch at Galveston · US

Funding

HHS HHSO10020170011I
6 · The paper itself

Abstract

The Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, recognizes that the evaluation of medical countermeasures under the Animal Rule requires well-characterized and reproducible animal models that are likely to be predictive of clinical benefit. Marburg virus (MARV), one of two members of the genus

Indexed as

MarburgvirusMarburg Virus DiseaseMedical CountermeasuresAnimalsHumansMacaca fascicularisViremiaFDAfilovirusmacaquesMarburg virusMARVnatural history studyvirus

Identifiers

PMID36298846
PMCPMC9607268
OpenAlexW4306772739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.